Vision

2. Vision To be the leading provider of integrated solutions that advance the understanding of genetics and health.

3. History • Founded April 1998 • David Walt, Ph.D., CW Group (Larry Bock), John Stuelpnagel, D.V.M., Anthony Czarnik, Ph.D., and Mark Chee, Ph.D • SNP genotyping services in 2001 • Illumina BeadLab in 2002

4. Management JAY T. FLATLEY President & Chief Executive Officer

5. Technology

6. Portfolio

7. Focused Research Strategy

8. Discovery Strategy

9. Molecular Dx Strategy

10. High Growth Markets Business Strategy

11. High Growth Markets Projected Growth • Molecular Diagnostics – 30% • Genotyping – 20% • DNA Sequencing – 10.4% • Gene Expression – 4%

12. Business Strategy Illumina Acquisitions and Investments

13. Illumina Acquisitions and Investments Industrial Consumer deCODE Genetics Mayo Clinic Children’s Hospital of Eastern Ontario CyVera Corporation Solexa Avantome GENpathway iGenix, inc.

14. Business Strategy Technology Leadership Expand Technologies

15. Business Strategy Illumina Acquisitions and Investments High Growth Markets Technology Leadership Industry standard in the genetic analysis markets! Expand Technologies

16. Throughput High Margin Consumables Platforms Markets Production Costs Low Margin Business Model

17. Financial Highlights • New and high-growth markets • Technology evolving rapidly • Sales - 98.3% compounded annual growth rate from 2005 to 2008. • EPS increased from ($0.13) in 2005 to $0.65 in 2008.

18. Financial Highlights Valuation Market Capitalization $3.59 billion Shares outstanding 125.09 million Price $28.70 P/E (ttm): 39.81 Beta 0.45 Sales 2007  $366,800 98.7% 2008 $573,225 56.2%2009 (Est.) $654,350 14.1% Profitability (ttm) Operating Margin 21.5% Profit Margin 15.1% Balance Sheet (Q3 2009) Total Assets $1,547,716 Total Liabilities $539,596 Total Stockholder Equity $1,002,120 Cash $238,528 Current Ratio 2.5

19. Stock Performance

20. Thank youAny questions?

21. Backup-How They Work